🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jonathan A. Ledermann

University College Hospital

ORCID: 0000-0003-3799-3539

Also affiliated with London Cancer, CRUK Lung Cancer Centre of Excellence, University College London

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma”.

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

OC-0369: Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3

Radiotherapy and Oncology(2020)10.1016/s0167-8140(21)00393-5

N/A

0DataRank · unranked

1 citations

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette +19 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.05.009

N/A

0DataRank · unranked

636 citations

Tjalling Bosse, Carien L. Creutzberg, Gonzalo Giornelli, Philipp Harter, Florence Joly +7 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

Self-supervised deep learning for highly efficient spatial immunophenotyping

EBioMedicine(2023)10.1016/j.ebiom.2023.104769

N/A

0DataRank · unranked

8 citations

Khalid AbdulJabbar, Tami Grunewald, Ayse U. Akarca, Yeman Brhane Hagos, Faranak Sobhani +11 more

High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors

Ovarian Cancers(2017)10.1007/978-3-319-32110-3_12

N/A

0DataRank · unranked

0 citations

Jonathan A. Ledermann